AstraZeneca and BMS discuss mega-merger worth 577 trillion won

AstraZeneca and Bristol Myers Squibb are reported to have discussed a potential merger worth about $400 billion over the past few months.

If completed, the deal would create one of the world’s top four drugmakers by market value and significantly boost oncology and U.S. market strength.

The transaction could become the biggest pharma M&A deal ever, drawing intense antitrust scrutiny and reshaping competition in cancer drugs.

It also raises political and strategic questions, including concerns over a possible UK corporate relocation and the role of BMS’s key drugs such as Revlimid, Eliquis and Opdivo.